Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Open-Label, Multi-center Trial Comparing a Once-Weekly and Once-Monthly Long-Acting Subcutaneous Injectable Depot of Buprenorphine (CAM2038) to Buprenorphine Standard of Care in Adult Outpatients with Opioid Dependence

Trial Profile

A Randomised, Open-Label, Multi-center Trial Comparing a Once-Weekly and Once-Monthly Long-Acting Subcutaneous Injectable Depot of Buprenorphine (CAM2038) to Buprenorphine Standard of Care in Adult Outpatients with Opioid Dependence

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Feb 2019

At a glance

  • Drugs Buprenorphine (Primary) ; Buprenorphine; Naloxone
  • Indications Opioid abuse
  • Focus Registrational; Therapeutic Use
  • Acronyms DEBUT
  • Sponsors Camurus
  • Most Recent Events

    • 05 Feb 2019 According to a Camurus media release, top-line results are expected in late 2019.
    • 31 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top